BRCA2 and neoplasm: The tumor progressed rapidly, and the MDT discussion recommended genetic testing. The results showed no mutation in BRCA1 and BRCA2 while UGT1AI*6, UGT1A1*28, UGT1A1-3156 had gene polymorphism.